Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation
Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn how patients with Advanced Non-Small Cell Lung
Cancer (NSCLC) respond to the study drug Dasatinib. The study drug, Dasatinib, has been
approved by the U.S. Food and Drug Administration (FDA) for treatment of leukemia, but has
not been approved for the treatment of other kinds of cancer. The use of Dasatinib in this
study is considered experimental.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute